Skip to content

Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury

Safety Observation on Human Embryonic Stem Cell (hESC) Derived Mesenchymal Stem Cells(MSC) Like Cell for the Meniscus Injury

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03839238
Enrollment
18
Registered
2019-02-15
Start date
2019-01-04
Completion date
2020-09-30
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Injury

Brief summary

human embryonic stem cell derived mesenchymal stem cells like cell for the meniscus injury, and observe the safety of the cells for meniscus injury

Detailed description

Three different dosage of human embryonic stem cell derived mesenchymal stem cells like for meniscus injury patients, and observe the safety of the cells for meniscus injury.

Interventions

BIOLOGICALhESC derived MSC like cell

Different dosage of hESC derived MSC like cell for the meniscus injured patients

Sponsors

Chinese Academy of Sciences
CollaboratorOTHER_GOV
Tongji Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Grade Ⅰ-Ⅱ meniscus injury of knee joint * The patients who still have the pain of knee joint and/or limitation of the function after accepted 3 months of nonoperative treatment

Exclusion criteria

* Recent history of lower limb fractures or intra-articular drug injection * The patients who have meniscus injury of knee joint need the surgical repair * The patients who have the severe coagulation disorders, cardiopulmonary failure and so on * The women who are pregnant or nursing * There are electronic implants such as pacemakers in the body * The patients who are infected the HIV, the virus of hepatitis or syphilis * The patients who are alcoholism or drug user * The patients who have vestibular and balance disorders * The patients with severe cognitive impairment who cannot follow instructions to complete the treatment * The patients who don't sign the informed consent * The patients who have tumor * Immunodeficiency patients * The patients who have congenital or acquired knee malformation * Patients or researchers who are participating in other clinical trials believe that other reasons are not appropriate for clinical trials

Design outcomes

Primary

MeasureTime frameDescription
The change in number of adverse events based on the National Cancer Institute-Common Terminology Criteria for Adverse Events1 week, 1 month, 2months and 3 months after the injection of MSC Like CellAdverse events include:allergic reactions, local reactions or infections at the injection site and muscle or skeletal dysplasia

Secondary

MeasureTime frameDescription
Visual Analog Score for pain(VAS)baseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like CellVAS is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective pain. The scale range is from 0 to 10, the higher the score, the more severe the pain.
Range of knee motionbaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like Cellto use the goniometer to measure the range of knee motion
Lysholm Knee Scalebaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like CellThe scale is to assess the function of knee. The scale range is from 0 to 100, the higher the score, the more severe the knee problems. This scale includes 8 items, and the total score is the sum of these 8 items' scores. Individual items are scored differently, using individual scoring scales: 1. limp (0,3,5), 2. support (0,2,5), 3. locking (0,2,6,10,15), 4. instability (0,5,10,15,20,25), 5. pain (0,5,10,15,20,25), 6. swelling (0,2,6,10), 7. stair climbing (0,2,6,10), 8. squatting (0,2,4,5).
Ultrasound of knee jointbaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like CellUltrasound of knee joint
Global posture analysis systembaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like Cellto test the static balance
Dynamic balance testbaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like CellUse the dynamic posture evaluator
MRI of kneebaseline, 1 week, 1 month, 2months and 3 months after the injection of MSC Like CellMRI of knee

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 26, 2026